Chemocentryx Stock News

ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis. “European Union approval of TAVNEOS repre

The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021.

The holy grail for a biopharma company is to get a drug approved and out to market, a feat achieved by few, considering the rigorous demands of regulators. However,

Gainers: Cerus Corporation (CERS) +7%. ChemoCentryx (CCXI) +3%

After four consecutive sessions of losses, ChemoCentryx <> is on the rise after Raymond James noted the latest prescriber information on the companys ANCA vasculitis drug

G Medical Innovations (GMVD) +20%. ChemoCentryx (CCXI) +12%. Denali Therapeutics Inc. (DNLI) -13%. Immix Biopharma (IMMX) -11%.

A long, drawn out regulatory review weighed on the drugmaker's shares last year.

They're risky. But with the high risk comes the potential for high rewards.

ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.

ChemoCentryx Inc. (NASDAQ:CCXI) concluded the trading at $37.72 on Thursday, December 23 with a rise of 3.26% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $36.53 and 5Y monthly beta was reading 1.80 with its price kept floating in the range ChemoCentryx Inc. (CCXI) Outlook: Revisiting The Past For Future Insights Read More »

During the last session, ChemoCentryx Inc. (NASDAQ:CCXI)s traded shares were 6.65 million, with the beta value of the company hitting 1.79. At the end of the trading day, the stocks price was $34.38, reflecting an intraday gain of 1.30% or $0.44. The 52-week high for the CCXI share is $70.29, that puts it down -104.45 How Will ChemoCentryx Inc. (NASDAQ: CCXI) Look After It Drops -104.45% From Its Highs? Read More »

In the last trading session, 1.12 million ChemoCentryx Inc. (NASDAQ:CCXI) shares changed hands as the companys beta touched 1.81. With the companys per share price at $36.15 changed hands at $1.12 or 3.20% during last session, the market valuation stood at $2.71B. CCXIs last price was a discount, traded about -94.44% off its 52-week high ChemoCentryx Inc. (NASDAQ: CCXI) Stock Could Reward Investors With A -204.29% Loss Read More »

Morgan Stanley grew its stake in ChemoCentryx, Inc. (NASDAQ:CCXI) by 10.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 388,061 shares of the biopharmaceutical companys stock after buying an additional 35,607 shares during the period. Morgan Stanley owned 0.56% []

In last trading session, ChemoCentryx Inc. (NASDAQ:CCXI) saw 2.27 million shares changing hands with its beta currently measuring 1.80. Companys recent per share price level of $35.48 trading at -$0.8 or -2.21% at ring of the bell on the day assigns it a market valuation of $2.48B. That closing price of CCXIs stock is at ChemoCentryx Inc. (NASDAQ:CCXI) Has Made The 73.14% Recovery, Could Gain Another -98.11% Ahead Read More »